X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs GSK PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. GSK PHARMA WOCKHARDT LTD./
GSK PHARMA
 
P/E (TTM) x -15.6 63.6 - View Chart
P/BV x 2.6 10.2 25.0% View Chart
Dividend Yield % 1.3 1.2 104.2%  

Financials

 WOCKHARDT LTD.   GSK PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
GSK PHARMA
Mar-17
WOCKHARDT LTD./
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1293,838 29.4%   
Low Rs6272,637 23.8%   
Sales per share (Unadj.) Rs363.1354.2 102.5%  
Earnings per share (Unadj.) Rs-20.439.8 -51.4%  
Cash flow per share (Unadj.) Rs-7.042.9 -16.3%  
Dividends per share (Unadj.) Rs10.0030.00 33.3%  
Dividend yield (eoy) %1.10.9 122.9%  
Book value per share (Unadj.) Rs301.8236.9 127.4%  
Shares outstanding (eoy) m110.5584.70 130.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.49.1 26.5%   
Avg P/E ratio x-42.981.4 -52.7%  
P/CF ratio (eoy) x-125.975.5 -166.7%  
Price / Book Value ratio x2.913.7 21.3%  
Dividend payout %-48.975.4 -64.8%   
Avg Mkt Cap Rs m97,063274,216 35.4%   
No. of employees `0006.84.7 144.1%   
Total wages/salary Rs m9,6654,830 200.1%   
Avg. sales/employee Rs Th5,931.86,387.0 92.9%   
Avg. wages/employee Rs Th1,428.11,028.3 138.9%   
Avg. net profit/employee Rs Th-334.0717.1 -46.6%   
INCOME DATA
Net Sales Rs m40,14630,000 133.8%  
Other income Rs m1,143728 156.9%   
Total revenues Rs m41,28930,728 134.4%   
Gross profit Rs m1284,190 3.1%  
Depreciation Rs m1,489263 566.3%   
Interest Rs m2,2530-   
Profit before tax Rs m-2,4724,655 -53.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m-2111,744 -12.1%   
Profit after tax Rs m-2,2603,368 -67.1%  
Gross profit margin %0.314.0 2.3%  
Effective tax rate %8.537.5 22.8%   
Net profit margin %-5.611.2 -50.2%  
BALANCE SHEET DATA
Current assets Rs m46,16016,742 275.7%   
Current liabilities Rs m19,2587,202 267.4%   
Net working cap to sales %67.031.8 210.7%  
Current ratio x2.42.3 103.1%  
Inventory Days Days10152 194.4%  
Debtors Days Days9421 452.6%  
Net fixed assets Rs m40,1658,635 465.1%   
Share capital Rs m553847 65.3%   
"Free" reserves Rs m32,81419,222 170.7%   
Net worth Rs m33,36720,069 166.3%   
Long term debt Rs m31,90310 319,027.0%   
Total assets Rs m89,68730,038 298.6%  
Interest coverage x-0.1NM-  
Debt to equity ratio x1.00 191,878.0%  
Sales to assets ratio x0.41.0 44.8%   
Return on assets %011.2 -0.1%  
Return on equity %-6.816.8 -40.4%  
Return on capital %-0.325.5 -1.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,121528 1,727.4%   
Fx outflow Rs m2,1337,193 29.7%   
Net fx Rs m6,988-6,665 -104.8%   
CASH FLOW
From Operations Rs m-2,6952,360 -114.2%  
From Investments Rs m-6,8633,008 -228.1%  
From Financial Activity Rs m12,545-5,108 -245.6%  
Net Cashflow Rs m3,010260 1,156.5%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 2.3 10.2 22.5%  
FIIs % 7.7 23.8 32.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 15.4 100.0%  
Shareholders   67,757 102,036 66.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  ASTRAZENECA PHARMA  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 19, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - UNICHEM LAB COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS